Human norovirus transmission and evolution in a changing world

Nature Reviews Microbiology

Volumn 14, Issue 7, 2016, Pages 421-433

  De Graaf, Miranda ^a   Van Beek, Janko ^a   Koopmans, Marion P G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; HUMAN IMMUNOGLOBULIN; INTERFERON; NITAZOXANIDE; NOROVIRUS VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

BACTERIUM; GENETIC RECOMBINATION; GENETIC VARIABILITY; HOST CELL; HUMAN; IMMUNE RESPONSE; MOLECULAR EVOLUTION; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TROPISM; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION; CALICIVIRIDAE INFECTIONS; ECONOMICS; EPIDEMIC; FOOD; GASTROENTERITIS; GENETICS; IMMUNOCOMPROMISED PATIENT; PATHOGENICITY; PHYSIOLOGY; RISK FACTOR; TRANSMISSION; VIRAL TROPISM; VIROLOGY;

CALICIVIRIDAE INFECTIONS; DISEASE OUTBREAKS; EVOLUTION, MOLECULAR; FOOD; GASTROENTERITIS; HUMANS; IMMUNOCOMPROMISED HOST; NOROVIRUS; RISK FACTORS; VIRAL TROPISM;

EID: 84969791255     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro.2016.48     Document Type: Review

References (120)

1. Atmar, R. L., & Estes, M. K. The epidemiologic and clinical importance of norovirus infection. Gastroenterol. Clin. North Am. 35, 275-290 (2006
2. Atmar, R. L., et al. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14, 1553-1557 (2008
3. Teunis, P. F., et al. Norwalk virus: how infectious is it? J. Med. Virol. 80, 1468-1476 (2008
4. Marks, P. J., et al. Evidence for airborne transmission of Norwalk-like virus (NLV) in a hotel restaurant. Epidemiol. Infect. 124, 481-487 (2000
5. Verhoef, L., et al. Norovirus genotype profiles associated with foodborne transmission, 1999-2012. Emerg. Infect. Dis. 21, 592-599 (2015
6. Wikswo, M. E., & Hall, A. J. Outbreaks of acute gastroenteritis transmitted by person-To person contact-United States, 2009-2010. MMWR Surveill. Summ. 61, 1-12 (2012
7. Lysen, M., et al. Genetic diversity among food-borne and waterborne norovirus strains causing outbreaks in Sweden. J. Clin. Microbiol. 47, 2411-2418 (2009
8. Siebenga, J. J., et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 200, 802-812 (2009
9. Kroneman, A., et al. Data quality of 5 years of central norovirus outbreak reporting in the European Network for food-borne viruses. J. Public Health (Oxf) 30, 82-90 (2008
10. Harris, J. P., Edmunds, W. J., Pebody, R., Brown, D. W., & Lopman, B. A. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14, 1546-1552 (2008
11. Trivedi, T. K., et al. Clinical characteristics of norovirus-Associated deaths: a systematic literature review. Am. J. Infect. Control 41, 654-657 (2013
12. Siebenga, J. J., et al. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J. Infect. Dis. 198, 994-1001 (2008
13. Murata, T., et al. Prolonged norovirus shedding in infants =6 months of age with gastroenteritis. Pediatr. Infect. Dis. J. 26, 46-49 (2007
14. Jones, M. K., et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 346, 755-759 (2014
15. Vinje, J. Advances in laboratory methods for detection and typing of norovirus. J. Clin. Microbiol. 53, 373-381 (2015
16. Kroneman, A., et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J. Clin. Microbiol. 46, 2959-2965 (2008
17. de Graaf, M., et al. Emergence of a novel GII.17 norovirus-end of the GII.4 era? Euro Surveill. 20, 21178 (2015
18. Thorne, L. G., & Goodfellow, I. G. Norovirus gene expression and replication. J. Gen. Virol. 95, 278-291 (2014
19. Donaldson, E. F., Lindesmith, L. C., Lobue, A. D., & Baric, R. S. Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8, 231-241 (2010
20. Vongpunsawad, S., Venkataram Prasad, B. V., & Estes, M. K. Norwalk virus minor capsid protein VP2 associates within the VP1 shell domain. J. Virol. 87, 4818-4825 (2013
21. Debbink, K., Lindesmith, L. C., & Baric, R. S. The state of norovirus vaccines. Clin. Infect. Dis. 58, 1746-1752 (2014
22. Wobus, C. E., et al. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2, e432 (2004
23. Hoa Tran, T. N., Trainor, E., Nakagomi, T., Cunliffe, N. A., & Nakagomi, O. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J. Clin. Virol. 56, 185-193 (2013
24. Rodriguez-Lazaro, D., et al. Virus hazards from food, water and other contaminated environments. FEMS Microbiol. Rev. 36, 786-814 (2012
25. Le Guyader, F. S., Atmar, R. L., & Le Pendu, J. Transmission of viruses through shellfish: when specific ligands come into play. Curr. Opin. Virol. 2, 103-110 (2012
26. Verhoef, L., et al. An integrated approach to identifying international foodborne norovirus outbreaks. Emerg. Infect. Dis. 17, 412-418 (2011
27. Foodborne Disease Burden Epidemiology Reference Group 2007-2015. WHO estimates of the global burden of foodborne diseases (WHO, 2011
28. Ahmed, S. M., et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-Analysis. Lancet Infect. Dis. 14, 725-730 (2014
29. Rockx, B., et al. Natural history of human calicivirus infection: a prospective cohort study. Clin. Infect. Dis. 35, 246-253 (2002
30. Sukhrie, F. H., et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin. Infect. Dis. 54, 931-937 (2012
31. Sukhrie, F. H., Siebenga, J. J., Beersma, M. F., & Koopmans, M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J. Clin. Microbiol. 48, 4303-4305 (2010
32. Milbrath, M. O., Spicknall, I. H., Zelner, J. L., Moe, C. L., & Eisenberg, J. N. Heterogeneity in norovirus shedding duration affects community risk. Epidemiol. Infect. 141, 1572-1584 (2013
33. Debbink, K., et al. Within-host evolution results in antigenically distinct GII.4 noroviruses. J. Virol. 88, 7244-7255 (2014
34. Mattison, K., et al. Human noroviruses in swine and cattle. Emerg. Infect. Dis. 13, 1184-1188 (2007
35. Summa, M., von Bonsdorff, C. H., & Maunula, L. Pet dogs-A transmission route for human noroviruses? J. Clin. Virol. 53, 244-247 (2012
36. Souza, M., Azevedo, M. S., Jung, K., Cheetham, S., & Saif, L. J. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4 HS66 strain of human norovirus. J. Virol. 82, 1777-1786 (2008
37. Cheetham, S., et al. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80, 10372-10381 (2006
38. Caddy, S. L., et al. Evidence for human norovirus infection of dogs in the United Kingdom. J. Clin. Microbiol. 53, 1873-1883 (2015
39. Widdowson, M. A., et al. Detection of serum antibodies to bovine norovirus in veterinarians and the general population in the Netherlands. J. Med. Virol. 76, 119-128 (2005
40. Mesquita, J. R., et al. Presence of antibodies against genogroup VI norovirus in humans. Virol. J. 10, 176 (2013
41. Friesema, I. H., et al. Differences in clinical presentation between norovirus genotypes in nursing homes. J. Clin. Virol. 46, 341-344 (2009
42. Thorven, M., et al. A homozygous nonsense mutation (428GA) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 79, 15351-15355 (2005
43. Lindesmith, L., et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9, 548-553 (2003
44. Stanley, P., & Cummings, R. D. in Essentials of Glycobiology 2nd edn Ch. 13 (eds Varki, A., et al.) (Cold Spring Harbor Laboratory Press, 2009
45. Le Pendu, J., Ruvoen-Clouet, N., Kindberg, E., & Svensson, L. Mendelian resistance to human norovirus infections. Semin. Immunol. 18, 375-386 (2006
46. Currier, R. L., et al. Innate susceptibility to norovirus infections influenced by FUT2 genotype in a United States pediatric population. Clin. Infect. Dis. 60, 1631-1638 (2015
47. Atmar, R. L. Noroviruses-state of the art. Food Environ. Virol. 2, 117-126 (2010
48. Shirato, H., et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J. Virol. 82, 10756-10767 (2008
49. Hutson, A. M., Atmar, R. L., Graham, D. Y., & Estes, M. K. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185, 1335-1337 (2002
50. Frenck, R., et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J. Infect. Dis. 206, 1386-1393 (2012
51. Donaldson, E. F., Lindesmith, L. C., Lobue, A. D., & Baric, R. S. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225, 190-211 (2008
52. Tan, M., & Jiang, X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog. 6, e1000983 (2010
53. Taube, S., et al. Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner. J. Virol. 86, 5584-5593 (2012
54. Zakhour, M., et al. The αGal epitope of the histo-blood group antigen family is a ligand for bovine norovirus Newbury2 expected to prevent cross-species transmission. PLoS Pathog. 5, e1000504 (2009
55. Caddy, S., Breiman, A., le Pendu, J., & Goodfellow, I. Genogroup IV and VI canine noroviruses interact with histo-blood group antigens. J. Virol. 88, 10377-10391 (2014
56. Murakami, K., et al. Norovirus binding to intestinal epithelial cells is independent of histo-blood group antigens. PLoS ONE 8, e66534 (2013
57. Yazawa, S., et al. Blood group substances as potential therapeutic agents for the prevention and treatment of infection with noroviruses proving novel binding patterns in human tissues. PLoS ONE 9, e89071 (2014
58. Chan, M. C., Ho, W. S., & Sung, J. J. In vitro whole-virus binding of a norovirus genogroup II genotype 4 strain to cells of the lamina propria and Brunner's glands in the human duodenum. J. Virol. 85, 8427-8430 (2011
59. Duizer, E., et al. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85, 79-87 (2004
60. Taube, S., et al. A mouse model for human norovirus. mBio 4, e00450 13 (2013
61. Bok, K., et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108, 325-330 (2011
62. Chachu, K. A., LoBue, A. D., Strong, D. W., Baric, R. S., & Virgin, H. W. Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog. 4, e1000236 (2008
63. Karst, S. M., Wobus, C. E., Lay, M., Davidson, J., & Virgin, H. W. STAT1 dependent innate immunity to a Norwalk-like virus. Science 299, 1575-1578 (2003
64. Bui, T., et al. Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J. Gen. Virol. 94, 2005-2016 (2013
65. Jung, K., et al. The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS ONE 7, e41619 (2012
66. Parrino, T. A., Schreiber, D. S., Trier, J. S., Kapikian, A. Z., & Blacklow, N. R. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297, 86-89 (1977
67. Ayukekbong, J. A., et al. Pattern of circulation of norovirus GII strains during natural infection. J. Clin. Microbiol. 52, 4253-4259 (2014
68. Simmons, K., Gambhir, M., Leon, J., & Lopman, B. Duration of immunity to norovirus gastroenteritis. Emerg. Infect. Dis. 19, 1260-1267 (2013
69. Lindesmith, L. C., et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med. 12, e1001807 (2015
70. Reeck, A., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202, 1212-1218 (2010
71. Ramani, S., et al. Mucosal and cellular immune responses to Norwalk virus. J. Infect. Dis. 212, 397-405 (2015
72. Yi, W., et al. Escherichia coli O86 O antigen biosynthetic gene cluster and stepwise enzymatic synthesis of human blood group B antigen tetrasaccharide. J. Am. Chem. Soc. 127, 2040-2041 (2005
73. Rasko, D. A., Wang, G., Monteiro, M. A., Palcic, M. M., & Taylor, D. E. Synthesis of mono-And di fucosylated type I Lewis blood group antigens by Helicobacter pylori. Eur. J. Biochem. 267, 6059-6066 (2000
74. Ruvoen-Clouet, N., et al. Increase in genogroup II.4 norovirus host spectrum by CagA-positive Helicobacter pylori infection. J. Infect. Dis. 210, 183-191 (2014
75. Baldridge, M. T., et al. Commensal microbes and interferon-determine persistence of enteric murine norovirus infection. Science 347, 266-269 (2015
76. Li, L., et al. The fecal viral flora of California sea lions. J. Virol. 85, 9909-9917 (2011
77. Wu, Z., et al. Deciphering the bat virome catalog to better understand the ecological diversity of bat viruses and the bat origin of emerging infectious diseases. ISME J. 10, 609-620 (2015
78. Katayama, K., et al. Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology 299, 225-239 (2002
79. Siebenga, J. J., et al. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog. 6, e1000884 (2010
80. Bull, R. A., Eden, J. S., Rawlinson, W. D., & White, P. A. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog. 6, e1000831 (2010
81. Eden, J. S., et al. The emergence and evolution of the novel epidemic norovirus GII.4 variant Sydney 2012. Virology 450-451, 106-113 (2014
82. Lopman, B., et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 363, 682-688 (2004
83. Debbink, K., et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 208, 1877-1887 (2013
84. Lindesmith, L. C., et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5, e31 (2008
85. Boon, D., et al. Comparative evolution of GII.3 and GII.4 norovirus over a 31 year period. J. Virol. 85, 8656-8666 (2011
86. Kobayashi, M., et al. Molecular evolution of the capsid gene in norovirus genogroup I. Sci. Rep. 5, 13806 (2015
87. Iritani, N., et al. Genetic analysis of the capsid gene of genotype GII.2 noroviruses. J. Virol. 82, 7336-7345 (2008
88. Swanstrom, J., Lindesmith, L. C., Donaldson, E. F., Yount, B., & Baric, R. S. Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J. Virol. 88, 829-837 (2014
89. Bull, R. A., et al. Norovirus recombination in ORF1/ ORF2 overlap. Emerg. Infect. Dis. 11, 1079-1085 (2005
90. Eden, J. S., Tanaka, M. M., Boni, M. F., Rawlinson, W. D., & White, P. A. Recombination within the pandemic norovirus GII.4 lineage. J. Virol. 87, 6270-6282 (2013
91. Mahar, J. E., Bok, K., Green, K. Y., & Kirkwood, C. D. The importance of intergenic recombination in norovirus GII.3 evolution. J. Virol. 87, 3687-3698 (2013
92. Chang, K. O., Sosnovtsev, S. V., Belliot, G., King, A. D., & Green, K. Y. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353, 463-473 (2006
93. Belliot, G., et al. Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase. J. Virol. 79, 2393-2403 (2005
94. Subba-Reddy, C. V., Goodfellow, I., & Kao, C. C. VPg-primed RNA synthesis of norovirus RNA-dependent RNA polymerases by using a novel cell-based assay. J. Virol. 85, 13027-13037 (2011
95. Subba-Reddy, C. V., Yunus, M. A., Goodfellow, I. G., & Kao, C. C. Norovirus RNA synthesis is modulated by an interaction between the viral RNA-dependent RNA polymerase and the major capsid protein, VP1. J. Virol. 86, 10138-10149 (2012
96. Gairard-Dory, A. C., et al. Clinical usefulness of oral immunoglobulins in lung transplant recipients with norovirus gastroenteritis: a case series. Transplant. Proc. 46, 3603-3605 (2014
97. Florescu, D. F., Hill, L. A., McCartan, M. A., & Grant, W. Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr. Transplant. 12, 372-375 (2008
98. Chachu, K. A., et al. Antibody is critical for the clearance of murine norovirus infection. J. Virol. 82, 6610-6617 (2008
99. Green, K. Y. Norovirus infection in immunocompromised hosts. Clin. Microbiol. Infect. 20, 717-723 (2014
100. Rossignol, J. F., & El Gohary, Y. M. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24, 1423-1430 (2006
101. Siddiq, D. M., Koo, H. L., Adachi, J. A., & Viola, G. M. Norovirus gastroenteritis successfully treated with nitazoxanide. J. Infect. 63, 394-397 (2011
102. Woodward, J. M., et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am. J. Gastroenterol. 110, 320-327 (2015
103. Nice, T. J., et al. Interferon-cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347, 269-273 (2015
104. Chang, K. O., & George, D. W. Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J. Virol. 81, 12111-12118 (2007
105. Richardson, C., Bargatze, R. F., Goodwin, R., & Mendelman, P. M. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev. Vaccines 12, 155-167 (2013
106. Bernstein, D. I., et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J. Infect. Dis. 211, 870-878 (2015
107. Kocher, J., et al. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. J. Virol. 88, 9728-9743 (2014
108. Tamminen, K., Lappalainen, S., Huhti, L., Vesikari, T., & Blazevic, V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS ONE 8, e70409 (2013
109. van der Vries, E., et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 9, e1003343 (2013
110. Huynen, P., et al. Molecular epidemiology of norovirus infections in symptomatic and asymptomatic children from Bobo Dioulasso, Burkina Faso. J. Clin. Virol. 58, 515-521 (2013
111. Hickman, D., et al. The effect of malnutrition on norovirus infection. mBio 5, e01032 13 (2014
112. Frange, P., et al. Prevalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. J. Infect. Dis. 206, 1269-1274 (2012
113. Meeroff, J. C., Schreiber, D. S., Trier, J. S., & Blacklow, N. R. Abnormal gastric motor function in viral gastroenteritis. Ann. Intern. Med. 92, 370-373 (1980
114. Schwartz, S., et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 117, 5850-5856 (2011
115. Schreiber, D. S., Blacklow, N. R., & Trier, J. S. The small intestinal lesion induced by Hawaii agent acute infectious nonbacterial gastroenteritis. J. Infect. Dis. 129, 705-708 (1974
116. Troeger, H., et al. Structural and functional changes of the duodenum in human norovirus infection. Gut 58, 1070-1077 (2009
117. Desai, R., et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin. Infect. Dis. 55, 189-193 (2012
118. Huhti, L., et al. Norovirus GII 4 causes a more severe gastroenteritis than other noroviruses in young children. J. Infect. Dis. 203, 1442-1444 (2011
119. Chan, M. C., et al. Fecal viral load and norovirus-Associated gastroenteritis. Emerg. Infect. Dis. 12, 1278-1280 (2006
120. Kroneman, A., et al. Proposal for a unified norovirus nomenclature and genotyping. Arch. Virol. 158, 2059-2068 (2013